Replies to post #5049 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>…Margret Destrempes, Stephen Blash, David Melican, William Gavin, Yann Echelard and Susan Overton of GTC Biotherapeutics Inc.<

Thanks, genisi! I wonder how far into the future the commercialization of this technique might be. For now, GTC seems to be committed to the nuclear-transfer method licensed from Geron.

By the way, Yann Echelard spoke at the annual shareholders’ meeting and is GTC’s “point man” on rFVIIa. Regards, Dew

[dodah_2]

The IP that GTCB has acquired or shares is amazing. It reminds me of Monopoly in some ways, in that, while you're acquiring and building, you are poor as a church mouse, but, one day, it all comes together.... as in "unlocks value." Shades of Warren Buffett.

[floblu14]

Abstract from FASEB Journal plus E-mail Contact -

http://www.fasebj.org/cgi/content/abstract/fj.07-8935comv1

E-mail contact: [e-mail]

AAV -
http://en.wikipedia.org/wiki/Adeno-associated_virus